Through its subsidiary ImmunoPrecise Netherlands, IPA is purchasing BioStrand BV, BioKey BV, and BioClue BV, a group of Belgian biotech entities known collectively as BioStrand.
ImmunoPrecise Antibodies is a biotherapeutic company that supports its business partners to discover and develop novel antibodies against a broad range of target classes and diseases.
BioStrand offers AI methodology for analyzing biological data to identify patterns and drive innovation in precision medicine, drug and vaccine development. Additionally, BioStrand offers a cloud-based service to perform multi-omics research faster and more accurately, with more effective data analysis. The business of BioKey BV focuses on technology related to the identification of characteristic biological sequences in proteins. BioClue BV focuses on technology for performing, inherently linked with a microarray process and possible primary analysis.
“The addition of BioStrand’s next-generation capabilities in systems omics analysis further enhances IPA’s unique ability to serve as a single-source partner to support our clients’ in silico, in vitro and in vivo research,” said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies. “We believe the acquisition of BioStrand brings together a revolutionary combination that will change the way researchers approach and complete target and antibody discovery. We are excited to add BioStrand to the IPA family.”